文献速递肝病

系统综述与荟萃分析:不同标准下丙氨酸氨基转移酶水平正常的初治慢性乙型肝炎患者存在显著组织学改变

Systematic review with meta-analysis: Significant histological changes among treatment-naïve chronic hepatitis B patients with normal alanine aminotransferase levels by different criteria.
PubMed 文献 · Aliment Pharmacol Ther · 2023-08-08

本系统综述与荟萃分析检索PubMed和Embase至2023年5月15日,纳入23项研究共4010例初治慢性乙型肝炎患者,评估不同丙氨酸氨基转移酶正常上限标准下中度至重度坏死性炎症、显著纤维化和肝硬化的合并比例。结果显示,丙氨酸氨基转移酶正常上限40 IU/L内,上述比例分别为33%、32%和3%;正常上限30/19 IU/L内显著纤维化比例为30%,即使正常上限20 IU/L内仍达21%。

要点

  • 丙氨酸氨基转移酶正常上限40 IU/L内,约1/3初治慢性乙型肝炎患者存在显著组织学改变。
  • 丙氨酸氨基转移酶正常上限30/19 IU/L内,显著纤维化合并比例为30%。
  • 即使丙氨酸氨基转移酶正常上限20 IU/L内,显著纤维化比例仍约1/5。

核心结论

  • 丙氨酸氨基转移酶正常上限40 IU/L内,约1/3初治慢性乙型肝炎患者存在显著组织学改变。
  • 即使丙氨酸氨基转移酶正常上限20 IU/L内,显著纤维化比例仍约1/5。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase至2023年5月15日,纳入23项研究共4010例初治慢性乙型肝炎患者。
  • 采用随机效应模型合并不同丙氨酸氨基转移酶正常上限内患者的中度至重度坏死性炎症、显著纤维化和肝硬化比例。

主要发现

  • 丙氨酸氨基转移酶正常上限40 IU/L内,中度至重度坏死性炎症合并比例为33%(95% CI:26%-42%)。
  • 丙氨酸氨基转移酶正常上限40 IU/L内,显著纤维化合并比例为32%(95% CI:27%-38%)。
  • 丙氨酸氨基转移酶正常上限40 IU/L内,肝硬化合并比例为3%(95% CI:1%-5%)。
  • 丙氨酸氨基转移酶正常上限男性30 IU/L、女性19 IU/L内,显著纤维化合并比例为30%(95% CI:25%-34%;432例参与者)。
  • 丙氨酸氨基转移酶正常上限20 IU/L内,显著纤维化合并比例为21%(95% CI:11%-37%;361例参与者)。

关键数值与推荐

  • 丙氨酸氨基转移酶正常上限40 IU/L内:中度至重度坏死性炎症33%(95% CI:26%-42%),显著纤维化32%(95% CI:27%-38%),肝硬化3%(95% CI:1%-5%)。
  • 丙氨酸氨基转移酶正常上限男性30 IU/L、女性19 IU/L内:显著纤维化30%(95% CI:25%-34%;432例参与者)。
  • 丙氨酸氨基转移酶正常上限20 IU/L内:显著纤维化21%(95% CI:11%-37%;361例参与者)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The upper limits of normal (ULNs) of ALT are not consistent across the major international guidelines which may affect the eligibility for antiviral therapy for chronic hepatitis B (CHB). AIM: To estimate the proportions of histological changes among treatment-naïve patients with CHB within differently defined ALT ULNs. METHODS: We searched PubMed and Embase up to May 15th, 2023, to identify studies of treatment-naïve CHB patients with liver biopsies. We pooled proportions of moderate to severe necroinflammation, significant fibrosis, and cirrhosis in those patients within different ALT ULNs by using random-effect models. RESULTS: We included 23 studies with 4010 participants. Within ALT ULN at 40 IU/L, the pooled proportions of moderate to severe necroinflammation, significant fibrosis, and cirrhosis were 33% (95% CI: 26%-42%), 32% (95% CI: 27%-38%), and 3% (95% CI: 1%-5%), respectively. Within ALT ULN at 30 IU/L for men and 19 IU/L for women, the pooled proportion of significant fibrosis remained at 30% (95% CI: 25%-34%; 432 participants). However, it was 21% (95% CI: 11%-37%; 361 participants) even in those within ALT ULN at 20 IU/L. Subgroup analyses suggested a significantly higher proportion of significant fibrosis among studies with prospective design or enrolled patients' mean age >35 or >40 years. CONCLUSIONS: Significant histological changes occurred in approximately 1/3 of treatment-naïve CHB patients within ALT ULN at 40 IU/L, whereas the proportion of significant fibrosis was approximately 1/5 even in those within ALT ULN at 20 IU/L.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Li S, Shi L, Xu X, et al. Systematic review with meta-analysis: Significant histological changes among treatment-naïve chronic hepatitis B patients with normal alanine aminotransferase levels by different criteria. Aliment Pharmacol Ther. 2023. PMID: 37551720. doi:10.1111/apt.17658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。